The top 100 drugs: a 5-year outlook by therapeutic area, 2026–2031
$546bn of 2025 sales across 12 therapy areas, projected drug by drug with patent expiries, Medicare negotiated prices and new launches. See the method our ready-to-go reports use. Read the report →
Ready-to-go or built around your question
Ready-to-go
The standard report below, on any product in the catalogue. Fixed scope, fixed price, no scoping call.
- Global view plus EU5 and US detail
- Base, low and high scenarios, 2027–2031
- PDF report and Excel model
- Delivered in 5 business days
Portfolio pack
Five ready-to-go analyses ordered together: a therapy area, a competitor set or your own portfolio.
- Same standard scope per product
- One cross-product summary
- Delivered in 10 business days
Custom
Your markets, your question. For pipeline assets not yet approved, single-country deep-dives (Greece, Cyprus, the Balkans, any EU market), launch sequencing, in-licensing and deal screening.
- Scoping call and written proposal
- Your own scenarios and assumptions
- Timeline agreed in the proposal
The ready-to-go 5-year market analysis
- Executive summaryThe 5-year outlook in one page: peak-year range, key drivers and the risks that move it.
- Product and regulatory profileIndications, approvals and status in the EU and US, designations, label changes and exclusivity.
- Patient populationPrevalence, diagnosed and treated patients by market, from published epidemiology.
- Treatment landscapeStandard of care, guidelines and where the product sits in the treatment pathway.
- CompetitionMarketed competitors, late-stage pipeline, biosimilar and generic entry, and loss-of-exclusivity timing.
- Pricing and accessList-price and reimbursement context, HTA outcomes and access barriers by market.
- 5-year revenue scenariosBase, low and high cases for 2027–2031 by region, with uptake, share and price assumptions set out.
- Risks and catalystsUpcoming readouts, regulatory dates, patent events and policy changes that could change the forecast.
Sources: official regulator records (EMA, European Commission, FDA), company filings and reports, published literature and HTA decisions; each fact is referenced. Forecasts are modelled scenarios built on stated assumptions, not guarantees. Not investment advice.
Find your product
Every EU-authorised medicine in the EMA register and every FDA approval in our database. Not listed? Order it anyway: pipeline and unlisted products are covered as custom analyses.
2,527 products match.
| Product | Company | Therapeutic area | Market · date | |
|---|---|---|---|---|
| Feraccru ferric maltol | Norgine B.V. | Anemia, Iron-Deficiency | 🇪🇺 EU 2016-02-18 | Order → |
| Iblias octocog alfa Additional monitoring | Bayer AG | Hemophilia A | 🇪🇺 EU 2016-02-18 | Order → |
| Kovaltry octocog alfa | Bayer AG | Hemophilia A | 🇪🇺 EU 2016-02-18 | Order → |
| Zurampic lesinurad Additional monitoring | Grünenthal GmbH | Hyperuricemia | 🇪🇺 EU 2016-02-18 | Order → |
| Portrazza necitumumab Additional monitoring | Eli Lilly Nederland B.V. | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2016-02-15 | Order → |
| Vaxelis diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed) | MCM Vaccine B.V. | Meningitis, Haemophilus; Poliomyelitis; Tetanus; Diphtheria; Whooping Cough; Hepatitis B | 🇪🇺 EU 2016-02-15 | Order → |
| Caspofungin Accord caspofungin Generic | Accord Healthcare S.L.U. | Candidiasis; Aspergillosis | 🇪🇺 EU 2016-02-11 | Order → |
| Tagrisso osimertinib Accelerated assessment | AstraZeneca AB | Carcinoma, Non-Small-Cell Lung | 🇪🇺 EU 2016-02-01 | Order → |
| Armisarte (previously Pemetrexed Actavis) pemetrexed | Actavis Group PTC ehf | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2016-01-18 | Order → |
| Pemetrexed Accord pemetrexed Generic | Accord Healthcare S.L.U. | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2016-01-18 | Order → |
| Episalvan birch bark extract | Amryt AG | Wounds and Injuries; Wound Healing | 🇪🇺 EU 2016-01-14 | Order → |
| Lopinavir/Ritonavir Viatris (previously Ritonavir Mylan) lopinavir;ritonavir Generic | Viatris Limited | HIV Infections | 🇪🇺 EU 2016-01-14 | Order → |
| Oncaspar pegaspargase | Les Laboratoires Servier | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2016-01-14 | Order → |
| Spectrila asparaginase | Medac Gesellschaft fuer klinische Spezialpraeparate mbH | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 🇪🇺 EU 2016-01-14 | Order → |
| Benepali etanercept Biosimilar | Samsung Bioepis NL B.V. | Arthritis, Psoriatic; Arthritis, Rheumatoid; Psoriasis | 🇪🇺 EU 2016-01-13 | Order → |
| Briviact (in Italy: Nubriveo) brivaracetam | UCB Pharma SA | Epilepsy | 🇪🇺 EU 2016-01-13 | Order → |
| Eptifibatide Accord eptifibatide Generic | Accord Healthcare S.L.U. | Myocardial Infarction | 🇪🇺 EU 2016-01-11 | Order → |
| Imlygic talimogene laherparepvec ATMP | Amgen Europe B.V. | Melanoma | 🇪🇺 EU 2015-12-16 | Order → |
| Ciambra pemetrexed Generic | Menarini International Operations Luxembourg S.A. | Carcinoma, Non-Small-Cell Lung; Mesothelioma | 🇪🇺 EU 2015-12-02 | Order → |
| Nucala mepolizumab | GlaxoSmithKline Trading Services Limited | Asthma | 🇪🇺 EU 2015-12-01 | Order → |
Order a report or brief us
We confirm scope and send the invoice by e-mail; work starts on confirmation.